Back to top
more

Aeglea BioTherapeutics, Inc. (AGLE)

(Delayed Data from NSDQ)

$7.82 USD

7.82
339,203

+0.07 (0.90%)

Updated Mar 3, 2021 04:00 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.41%
2Buy17.88%
3Hold9.48%
4Sell5.03%
5Strong Sell1.87%
S&P50010.70%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 21% (201 out of 254)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Aeglea (AGLE) Upgraded to Buy: Here's Why

Aeglea (AGLE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Is a Surprise Coming for Aeglea (AGLE) This Earnings Season?

Aeglea (AGLE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zoetis (ZTS) to Report Q3 Earnings: What's in the Cards?

Zoetis (ZTS) will provide updates on earnings, revenues and other pipeline developments when its releases third-quarter 2020 results.

Aeglea (AGLE) Looks Good: Stock Adds 5.8% in Session

Aeglea (AGLE) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Here's Why Momentum Investors Will Love Aeglea Biotherapeutics (AGLE)

Does Aeglea Biotherapeutics (AGLE) have what it takes to be a top stock pick for momentum investors? Let's find out.

Has Aeglea BioTherapeutics (AGLE) Outpaced Other Medical Stocks This Year?

Is (AGLE) Outperforming Other Medical Stocks This Year?

Aeglea BioTherapeutics (AGLE) Catches Eye: Stock Jumps 5.1%

Aeglea BioTherapeutics (AGLE) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Has Aeglea BioTherapeutics (AGLE) Outpaced Other Medical Stocks This Year?

Is (AGLE) Outperforming Other Medical Stocks This Year?

Why Aeglea BioTherapeutics (AGLE) Stock Might be a Great Pick

Aeglea BioTherapeutics (AGLE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks.com featured highlights include: Aeglea BioTherapeutics and Passage Bio

Zacks.com featured highlights include: Aeglea BioTherapeutics and Passage Bio

Shrabana Mukherjee headshot

New Analyst Coverage Puts Spotlight on These 2 Stocks

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

Aeglea BioTherapeutics' Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Aeglea BioTherapeutics

Menlo Therapeutics (MNLO) Catches Eye: Stock Jumps 7.1%

Menlo Therapeutics (MNLO) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Is Aeglea BioTherapeutics (AGLE) Outperforming Other Medical Stocks This Year?

Is (AGLE) Outperforming Other Medical Stocks This Year?

Zacks.com featured highlights include: Aeglea BioTherapeutics, VeriSign, Sequans Communications and New Jersey Resources

Zacks.com featured highlights include: Aeglea BioTherapeutics, VeriSign, Sequans Communications and New Jersey Resources

Shrabana Mukherjee headshot

4 Stocks in the Limelight on New Analyst Coverage

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

Benjamin Rains headshot

Find Strong Stocks During the Coronavirus with New Analyst Coverage

Today we screened for strong stocks that recently received new analyst coverage...

Is Aeglea BioTherapeutics (AGLE) Stock a Solid Choice Right Now?

Aeglea BioTherapeutics (AGLE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Aeglea BioTherapeutics, Inc. (AGLE) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Aeglea BioTherapeutics, Inc. (AGLE).

Aeglea (AGLE) Upgraded to Strong Buy: What Does It Mean for the Stock?

Aeglea (AGLE) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Aeglea (AGLE) Reports New Positive Data for Pegzilarginase

Aeglea (AGLE) reports new positive data for pegzilarginase in patients with Arginase 1 Deficiency.

Dermira (DERM) Gains 5% in a Week, Post-Qbrexa Approval

Shares of Dermira, Inc. (DERM) increase about 5% after the FDA approved its excessive underarm sweating drug, Qbrexza.

Sarepta's DMD Portfolio Solid, Sole Drug Dependence Concerns

Sarepta Therapeutics' (SRPT) DMD drug sales are rising and pipeline candidates are progressing well. However, dependence on a single product for near-term growth is a concern.

Alkermes' Aristada Initio Approved by FDA for Schizophrenia

FDA approves Alkermes' (ALKS) Aristada Initio (aripiprazole lauroxil) for the treatment of schizophrenia in adults.

Roche's Breast Cancer Study Meets Co-Primary Endpoint

Phase III IMpassion130 study shows that Roche???s (RHHBY) Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer.